The Impact of Preclinical Irreproducibility on Drug Development

E-ISSN： 1532-6535|97|1|16-18

ISSN： 0009-9236

Source： CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.97, Iss.1, 2015-01, pp. : 16-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Impact of Obesity on Development and Progression of Mammary Tumors in Preclinical Models of Breast Cancer

By Cleary Margot

Journal of Mammary Gland Biology and Neoplasia, Vol. 18, Iss. 3-4, 2013-12 ,pp. : 333-343

Springer Publishing Company

Access to resources Recommend Favorite

Impact of biomarker usage on oncology drug development

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 38, Iss. 1, 2013-02 ,pp. : 62-67

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of biomarker usage on oncology drug development

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 269-4727, Iss. 1, 2013-02 ,pp. : 62-67

John Wiley & Sons Inc

Access to resources Recommend Favorite

Discovery and preclinical development of new antibiotics

By Hughes Diarmaid Karlén Anders

Upsala Journal of Medical Sciences, Vol. 119, Iss. 2, 2014-05 ,pp. : 162-169

Informa Healthcare

Access to resources Recommend Favorite

Preclinical Development of a Vaccine ‘Against Smoking’

Oncology Research and Treatment, Vol. 25, Iss. 5, 2002-11 ,pp. : 406-411

Karger

Access to resources Recommend Favorite